Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study

BackgroundThe global trend toward delayed childbearing has led to an increased use of fertility treatment, including in vitro fertilization (IVF) and hormonal medications. Concerns regarding the potential impact of these interventions on breast cancer risk, particularly among high-risk women with a pathogenic variant in the BRCA1 or BRCA2 genes remains an important clinical concern.MethodsWe conducted a matched case–control analysis of women carrying a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 enrolled in a longitudinal, international study. The analysis included 4,145 women with invasive breast cancer (cases) and 4,145 matched controls without breast cancer. Data on infertility and use of fertility treatments was collected by a research questionnaire. Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between infertility, fertility medications, and IVF, with the risk of breast cancer. Multivariable models were adjusted for parity and oral contraceptive use.ResultsAmong the 8,290 participants, 12% reported a history of infertility, 5% had used fertility medication, and 1% had undergone IVF. There was no statistically significant association between a history of infertility (OR = 0.96; 95% CI 0.84–1.10), use of any type of fertility medication (OR = 1.10; 95% CI 0.90–1.34), or IVF specifically (OR = 1.15; 95% CI 0.76–1.73) and the risk of BRCA-breast cancer. Findings were similar in the adjusted analyses.ConclusionsFindings from this large, international study found no evidence for an association between infertility or fertility treatment and the risk of breast cancer among BRCA1 or BRCA2 carriers. Although based on low rates of exposure, these findings provide some reassurance to BRCA carriers considering fertility treatment. Future studies evaluating impact of contemporary protocols are needed.